Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.

October 13, 2017

Milestone on Bayer's path to completing the planned acquisition of Monsanto:Bayer signs agreement to sell selected Crop Science businesses to BASF for EUR 5.9 billion

Package includes global glufosinate-ammonium business and selected seeds activities / Assets generated total sales of EUR 1.3 billion in 2016 / Sale is subject to successful closing of Bayer’s acquisition of Monsanto / BASF has committed to maintain employment for all transferring permanent employees for at least three years post closing Read more
September 12, 2017

Wolfgang Nickl to be new Chief Financial Officer at Bayer AG

Read more
August 28, 2017

In Canadian-Led Phase III Clinical Study, Xarelto® when Combined with ASA Significantly Lowered the Combined Risk of Stroke, Cardiovascular Death, and Heart Attack in Patients with Chronic Coronary or Peripheral Artery Disease by 24%

Read more
August 01, 2017

K9 Advantix® II approved for killing mosquitoes and reducing biting by mosquitoes and stable flies

Read more
July 07, 2017

RestoraLAX® recall expanded to include RestoraLAX 30+7 Bonus Packs

Read more
June 22, 2017

Bayer selects three Canadian startups for Grants4Apps® Toronto 2017 program

Supporting growth of digital healthcare in Canada part of Bayer Open Innovation Read more
May 05, 2017

Thousands of Canadians will benefit from a new training tool for surgeons

The National Research Council of Canada (NRC), with the support of Bayer Inc. through an innovation fund, has developed a first-of-its-kind pulmonary endarterectomy (PEA) surgery simulator that has the potential to improve the quality of life for thousands of Canadian patients. Read more
April 11, 2017

Bayer launches Grants4AppsToronto

Three digital health startups, 88 days and a once in a lifetime opportunity to be mentored by a global leader in life sciences Read more
March 20, 2017

Bayer's Canadian contraception family is growing with the launch of Kyleena®.

Kyleena is an effective, low-dose, five-year birth control option that women don't have to worry about taking every day. Read more
December 12, 2016

Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing

BlueRock Therapeutics is focused on breakthrough treatments based on latest stem cell technology in combination with superior cell differentiation protocols. BlueRock Therapeutics’ vision is to cure diseases with significant cell loss and diminished self-repair potential with an initial focus on cardiovascular, neurological and other conditions. Read more